Logo Image
|Videos|December 10, 2020

Supplements and Featured Publications

  • The Evidence for Oral Semaglutide in Type 2 Diabetes From a Managed Care Perspective

Full Video Abstract: Evidence for Oral Semaglutide in Type 2 Diabetes

This infographic to The American Journal of Managed Care® supplement, "The Evidence for Oral Semaglutide in Type 2 Diabetes From a Managed Care Perspective," describes key managed care information on the role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the management of type 2 diabetes in the United States, and appraises the clinical evidence for the first oral GLP-1RA, oral semaglutide.

Click here to read the full supplement to this video abstract.

Articles in this issue

over 5 years ago

The Evidence for Oral Semaglutide in Type 2 Diabetes From a Managed Care Perspective

over 5 years ago

Type 2 Diabetes in the US Managed Care Setting: The Burden of Disease and Rationale for an Oral Glucagon-like Peptide-1 Receptor Agonist

over 5 years ago

Efficacy of Oral Semaglutide: Overview of the PIONEER Clinical Trial Program and Implications for Managed Care

over 5 years ago

Cardiovascular Outcomes, Safety, and Tolerability With Oral Semaglutide: Insights for Managed Care

over 5 years ago

The Importance of Patient-Reported Outcomes in Type 2 Diabetes: Insight From the PIONEER Program With Oral Semaglutide

over 5 years ago

Participating Faculty for the Evidence for Oral Semaglutide in Type 2 Diabetes From a Managed Care Perspective

Related Content